EMDAC

(redirected from Endocrinologic and Metabolic Drugs Advisory Committee)
AcronymDefinition
EMDACEndocrinologic and Metabolic Drugs Advisory Committee (US FDA)
EMDACEMS (Emergency Medical Services) Medical Directors Association of California
EMDACEast Midlands Dog Agility Club (UK)
References in periodicals archive ?
The Endocrinologic and Metabolic Drugs Advisory Committee of the U.S.
But the drug barely squeaked by its June FDA approval hearing for the cardioprotective indication, receiving a split 12-11 endorsement from the Endocrinologic and Metabolic Drugs Advisory Committee. The major sticking point was that EMPA-REG was a test of empagliflozin's cardiovascular safety, not its efficacy, and that cardiovascular death was not a prespecified endpoint.
Konstam, MD, a temporary member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) and chief physician executive of the cardiovascular center at Tufts Medical Center in Boston.
According to an article that discussed the approval process for evolocumab, 11 of the f4 members of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) thought that the benefits of lowering LDL-C outweighed the risks for patients with HeFH--a gene mutation that affects the LDL-C receptors in the liver.
Merck, known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S.
Last week, the insulins were recommended for regulatory approval by the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA).
This approval was recommended by the US Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee, which voted 20 to two.
23 December 2011 - VIVUS Inc (NASDAQ:VVUS) said on Friday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA) will review the company's application for the approval of Qnexa for the treatment of obesity on 22 February 2012.
The Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration (FDA) did not support the approval of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The Endocrinologic and Metabolic Drugs Advisory Committee with the FDA's Center for Drug Evaluation and Research heard testimony from Eli Lilly and Co., the drug's manufacturer, that children and adults with short stature may experience psychosocial harm and other disadvantages compared with their peers.
Konstam, a temporary member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) and chief physician executive of the cardiovascular center at Tufts Medical Center in Boston.